Latest Headlines

Latest Headlines

Big Pharma's new PCSK9, heart failure meds stuck in the slow lane. What gives?

In noting Q4 sales of Sanofi and Regeneron's brand-new PCSK9 med Praluent--€5 million, a far cry from analyst estimates of €41 million or more--Bernstein analyst Tim Anderson said the big shortfall "is likely to bring scrutiny, as yet another example of slow uptake of a new medicine."

After a big 2015, Regeneron predicts slowing 2016 sales for launch superstar Eylea

Last month, Regeneron announced 2015 Eylea sales that had investors excited. But that didn't soften the blow on Tuesday, when it warned that the med's growth in the U.S. would slow down.

UPDATED: NICE, in reversal, OKs Amgen's Repatha while snubbing Sanofi and Regeneron's Praluent

Amgen's Repatha is in a market brawl with Sanofi and Regeneron's Praluent as the competitors rush to sew up as many OKs around the world as possible for the new-gen cholesterol fighters following their FDA approval last year within weeks of one another. Now Amgen has pulled ahead in England after the country's drug pricing watchdog has both changed course to cover Repatha for some patients, while dealing its competitors a blow with a rejection for Praluent.

Sanofi and Regeneron likely to cough up royalties to end Amgen's PCSK9 patent suit: Analyst

One of the hottest races for market share in pharma these days is between Amgen's cholesterol-fighter Repatha and Praluent, from Sanofi and Regeneron. They're apparently neck and neck with payers, and their script numbers aren't much different either, at least so far.

Sanofi and Regeneron line up for FDA approval with an arthritis treatment

Sanofi and Regeneron are moving toward FDA approval with what could be their second blockbuster collaboration, preparing to make the case for a new treatment for rheumatoid arthritis.

Top-earning directors on the S&P 500? Regeneron and Endo, at $1.4M and up

Biopharma CEOs pull down some hefty pay packages, with Regeneron chief Len Schleifer topping the list last year at $42 million. But as lucrative as that may be, it's not nearly as much as the highest-paid U.S. CEOs overall.

UPDATED: Sanofi's and Regeneron's Praluent wins top billing on UnitedHealth Group's formulary

Sanofi and Regeneron's Praluent will be UnitedHealth Group's "preferred" drug for treating superhigh LDL cholesterol. The partners said that UnitedHealth Group will provide preferred access to both doses for the injected Praluent through OptumRx and UnitedHealthcare across a spectrum of commercial, Medicare, and Managed Medicaid patients.

Sanofi's Praluent scores first place in line for UnitedHealth unit's PCSK9 patients

Here's one way to privilege a new drug over its rival without blocking one entirely: Make patients try your favored product first. That's what UnitedHealth's Oxford unit is doing with the two new cholesterol-fighting PCSK9 drugs, Bloomberg reports, citing a policy update.

Sanofi, Regeneron prepped PCSK9 rollout with 'Cholesterol Counts' campaign

No question that the marketing people at Sanofi were excited about alirocumab, the next-generation cholesterol drug that won approval earlier this year. Analysts had been talking about multibillion-dollar sales, and recent trial data--not just from Sanofi and its partner Regeneron--built optimism even further.

Regeneron plots a $150M R&D expansion, adding 300 jobs at its New York hub

Regeneron Pharmaceuticals, riding high with a top-selling eye drug and some promising pipeline assets, is planning to invest $150 million in its native New York, supporting 300 new jobs at its fast-growing R&D campus.